Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00442221 · ClinicalTrials.gov registry record · Phase 3
The Safety Of Combo Formulation In The Treatment Of Multiple Episodes Of Acute Migraine Over 12 Months
A Phase 3 study, sponsored by POZEN.
- Completed
- Registry status
- Phase 3
- Development phase
- 500
- Enrollment target
NCT00442221 is a Phase 3 study that has completed, run by POZEN. The registered enrollment target is 500 participants.
The verdict
NCT00442221, a Phase 3 study, has completed, sponsored by POZEN.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 500 participants
- Enrollment target
Study Summary
The objective of this study is to assess the safety of a single-tablet dose of Combo Formulation for the treatment of moderate to severe migraines
Interventions
- DRUG Sumatriptan and Naproxen sodium
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2004-05 |
| Est. Completion | 2004-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00442221
The ClinicalTrials.gov registry entry for NCT00442221 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 500 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is POZEN, which has 24 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Sumatriptan and Naproxen sodium is the first listed.
NCT00442221 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00442221 about?
NCT00442221 is a clinical study titled "The Safety Of Combo Formulation In The Treatment Of Multiple Episodes Of Acute Migraine Over 12 Months". The objective of this study is to assess the safety of a single-tablet dose of Combo Formulation for the treatment of moderate to severe migraines
What is the current status of trial NCT00442221?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 500 participants. The study started on 2004-05. Estimated completion is 2004-08.
What interventions are being tested in trial NCT00442221?
The interventions under investigation include: Sumatriptan and Naproxen sodium (DRUG).
Who is sponsoring clinical trial NCT00442221?
This trial is sponsored by POZEN, which has 24 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.